Incidence and Clinical Course of Intraocular Inflammation Following Pharmacy-Compounded Intravitreal Aflibercept 8mg for Neovascular AMD: A Real-World Cohort Study
Jan Kucharczuk, Hubert Kasprzak, Marlena Tuchowska-Celej, Maciej Gawęcki · 2026
Read Incidence and Clinical Course of Intraocular Inflammation Following Pharmacy-Compounded Intravitreal Aflibercept 8mg for Neovascular AMD: A Real-World Cohort Study by Jan Kucharczuk, Hubert Kasprzak, Marlena Tuchowska-Celej, Maciej Gawęcki (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13592338.txt.
Description
Jan Kucharczuk, Hubert Kasprzak, Marlena Tuchowska-Celej, and Maciej Gawęcki tracked eye inflammation after injections of a high-dose eye drug in Poland, in a 2026 paper. The drug treats wet age-related macular degeneration, a leading cause of vision loss. At their hospital, pharmacists split each vial into two doses. The team reviewed 867 patients who received more than three thousand injections during 2025, then followed inflammation cases for six months.
Inflammation struck about two in a hundred patients, a higher rate than in the drug's trials. Symptoms began about three days after injection, and vision dipped. Most cases settled with steroid drops or injections; one patient needed surgery. No dangerous vessel inflammation appeared, and retinal thickness stayed stable. The authors judge the episodes mostly mild, with no lasting harm to sight. They offer the findings to guide monitoring of patients on this drug.
Catalog record
| CREATOR | Jan Kucharczuk, Hubert Kasprzak, Marlena Tuchowska-Celej, Maciej Gawęcki |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |